Clinical Trial Update: A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation [Phase 1, Phase 2]

View source ↗

Summary

This is an ongoing Phase 1/2 clinical trial evaluating divarasib as a single agent or in combination with other anti-cancer therapies in previously untreated ad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Divarasib

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING